BioCentury
ARTICLE | Clinical News

Protarga begins Taxoprexin Phase II trial

June 6, 2001 7:00 AM UTC

Protarga (King of Prussia, Penn.) began a U.S. Phase II study of its Taxoprexin docosahexaenoic acid-linked paclitaxel to treat advanced renal cell carcinoma. The trial is the first U.S. study of Taxo...